A quick search of the literature did not yield any specific double-blind, randomised placebo-controlled clinical trials on the efficacy of Methylene Blue as an effective treatment for malaria or as a lithium treatment supplement over a two-year trial period. However, there have been some studies that suggest potential benefits from using Methylene Blue in these contexts.
Methylene Blue was originally used as an anti-malarial agent before the advent of more modern treatments. Some recent research has shown promise for its use in treating malaria, particularly drug-resistant forms. For instance, a clinical trial conducted by Meissner et al., (2005) found methylene blue to be effective against Plasmodium falciparum malaria when combined with other antimalarial drugs.
As for its role in lithium treatment supplement, this is less clear. There are experimental studies suggesting that methylene blue might have neuroprotective effects and could potentially be useful in diseases such as bipolar disorder where lithium is commonly used. However, much more research would be needed to confirm these findings and determine appropriate dosing and safety protocols.
Therefore, while there is some evidence to suggest that Methylene Blue may have potential uses in both malaria treatment and as a lithium supplement, no specific large-scale double-blind randomised controlled trials over two years have been identified at this time. More research is necessary to further explore these possibilities and establish solid evidence for their effectiveness.